Olmetec and Cystitis aggravated - a phase IV clinical study of FDA data

Summary:

Cystitis aggravated is reported as a side effect among people who take Olmetec (olmesartan medoxomil), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Amlodipine, and have Rheumatoid arthritis.

The phase IV clinical study analyzes which people have Cystitis aggravated when taking Olmetec. It is created by eHealthMe based on reports of 7,816 people who have side effects when taking Olmetec from the FDA, and is updated regularly.

What is Olmetec?

Olmetec has active ingredients of olmesartan medoxomil. It is often used in high blood pressure. eHealthMe is studying from 7,904 Olmetec users. Check the latest studies of Olmetec.

What is Cystitis aggravated?

Cystitis aggravated (inflammation of the wall of the bladder) is found to be associated with 2,014 drugs and 768 conditions by eHealthMe. Check the latest studies of Cystitis aggravated.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 30, 2026

7,816 people reported to have side effects when taking Olmetec.
Among them, 258 people (3.3%) have Cystitis aggravated.

Could Olmetec cause Cystitis aggravated?

Among these 258 people:

How long have people been on Olmetec when they have Cystitis aggravated? *

Click here to view more results

What is the gender of people who have Cystitis aggravated when taking Olmetec? *

Click here to view

* Approximation only. Some reports may have incomplete information.

Do you take Olmetec and have Cystitis aggravated?

- Check whether Cystitis aggravated is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Olmetec:

Olmetec (7,904 reports)

Cystitis aggravated treatments and more:

Cystitis aggravated (15 reports)

How severe was Cystitis aggravated and when was it recovered:

Cystitis aggravated in Olmetec

Expand to all the drugs that have ingredients of olmesartan medoxomil:

Cystitis aggravated and drugs with ingredients of olmesartan medoxomil

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Olmetec:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Cystitis aggravated:

Cystitis aggravated (2,014 drugs)

Browse all the conditions that are associated with Cystitis aggravated:

Cystitis aggravated (768 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on olmesartan medoxomil (the active ingredients of Olmetec) and Olmetec (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.